Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor® (rexlemestrocel-L) an Orphan-Drug Designation (ODD) following submission of results from the randomized controlled trial in children with hypoplastic left heart […]
SOUTH MUMBAI BASED 60+ YEAR OLD CMJ JAIN Hospital introduces IN A FIRST AS A CHARITABLE HOSPITAL, robotic surgery on SSI Mantra platform
CMJ Hospital, a beacon of healthcare for the poor & needy in Girgaon, Mumbai, with a legacy spanning 60+ years, has announced a groundbreaking advancement in surgical care with the introduction of robotic surgery on the SSI Mantra platform. This initiative is aligned with CMJ Hospital’s commitment to providing world-class […]
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the Company’s first indication-specific drug registration for Trunerox™ issued by INVIMA, the Health Authority of Colombia. “The approval of our […]
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from a study conducted at two medical centers, Beit Rivka Hospital, and Rabin Medical Center, both in Petah Tikva and owned […]
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers and identified through Numab’s proprietary discovery and engineering technology platform. Under the terms of the […]
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
Invitae (OTC: NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the Company intends to safeguard its […]
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.” The paper evaluated a transplant of Sana’s engineered allogeneic, hypoimmune […]
FDA Advisory Committee Votes in Favor of Abbott’s First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve
Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug Administration (FDA) confirmed 13 to 1, with 0 abstention that the benefits of Abbott’s TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people […]
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as a first-line treatment in adults living with metastatic pancreatic adenocarcinoma (mPDAC). This is the second approval for […]
New Vision-Training Software Improves Low Vision
Marking the Low Vision awareness month of February, RevitalVision announced the expansion of their team in India as part of their commitment to make their US FDA-cleared vision-training software program available to maximum eye specialists in India to support their patients in improving their vision. RevitalVision is a unique perceptual-learning […]
